{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:09:18Z","timestamp":1776157758255,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/Z504142\/1"],"award-info":[{"award-number":["MR\/Z504142\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejso.2026.111412","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T07:35:27Z","timestamp":1768635327000},"page":"111412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Normothermic catheter-based intraperitoneal chemotherapy: Systematic review using the IDEAL framework"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5847-495X","authenticated-orcid":false,"given":"Becky","family":"Leveridge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3603-913X","authenticated-orcid":false,"given":"Edagul","family":"Ulucay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4898-2173","authenticated-orcid":false,"given":"Henry D.","family":"Robb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-0010","authenticated-orcid":false,"given":"Alice E.","family":"Baggaley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2081-5701","authenticated-orcid":false,"given":"Christopher J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George B.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Petty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piers R.","family":"Boshier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2026.111412_bib1","article-title":"Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: results from the multicenter, randomized, phase 3 DRAGON-01 trial","volume":"43","author":"Yan","year":"2025","journal-title":"J Clin Orthod"},{"issue":"2","key":"10.1016\/j.ejso.2026.111412_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.109499","article-title":"Outcomes of intraperitoneal chemotherapy for the treatment of gastric cancer with peritoneal metastasis: a comprehensive systematic review and meta-analysis","volume":"51","author":"Boshier","year":"2025","journal-title":"Eur J Surg Oncol"},{"issue":"9695","key":"10.1016\/j.ejso.2026.111412_bib3","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(09)61116-8","article-title":"No surgical innovation without evaluation: the IDEAL recommendations","volume":"374","author":"McCulloch","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejso.2026.111412_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/SLA.0000000000002794","article-title":"No surgical innovation without evaluation: evolution and further development of the IDEAL framework and recommendations","volume":"269","author":"Hirst","year":"2019","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ejso.2026.111412_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.canlet.2004.03.018","article-title":"Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer","volume":"210","author":"Yonemura","year":"2004","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.ejso.2026.111412_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3892\/or.2014.3210","article-title":"Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer","volume":"32","author":"Kinoshita","year":"2014","journal-title":"Oncol Rep"},{"issue":"3","key":"10.1016\/j.ejso.2026.111412_bib7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s10120-023-01368-3","article-title":"Exosomal hsa-let-7g-3p and hsa-miR-10395-3p derived from peritoneal lavage predict peritoneal metastasis and the efficacy of neoadjuvant intraperitoneal and systemic chemotherapy in patients with gastric cancer","volume":"26","author":"Luo","year":"2023","journal-title":"Gastric Cancer"},{"issue":"10","key":"10.1016\/j.ejso.2026.111412_bib8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00432-003-0481-3","article-title":"Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato (trans-R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles","volume":"129","author":"Verschraegen","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111412_bib9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10147-008-0836-5","article-title":"Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer","volume":"13","author":"Tamura","year":"2008","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.111412_bib10","first-page":"1305","article-title":"Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study","volume":"19","author":"Fushida","year":"2008","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.ejso.2026.111412_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35566","article-title":"Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology","volume":"131","author":"Badgwell","year":"2025","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ejso.2026.111412_bib12","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2174\/1389201019666181114121145","article-title":"Clinical efficacy of combination intravenous and intraperitoneal chemotherapy in the treatment of gastric cancer with peritoneal carcinomatosis","volume":"19","author":"Zhang","year":"2018","journal-title":"Curr Pharm Biotechnol"},{"issue":"8","key":"10.1016\/j.ejso.2026.111412_bib13","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1245\/s10434-022-11582-5","article-title":"Safety and efficacy of intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for gastric cancer with peritoneal metastasis","volume":"29","author":"Kang","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2026.111412_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4174\/astr.2021.100.4.209","article-title":"Treatment options for advanced gastric cancer with peritoneal metastasis: experience from a single institution in Korea","volume":"100","author":"Kim","year":"2021","journal-title":"Annal Surg Treat Res"},{"issue":"1","key":"10.1016\/j.ejso.2026.111412_bib15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.21037\/jgo.2019.11.05","article-title":"Bidirectional chemotherapy in patients with gastric cancer and peritoneal metastasis","volume":"11","author":"Martin","year":"2020","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2026.111412_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jso.21324","article-title":"Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery","volume":"100","author":"Yonemura","year":"2009","journal-title":"J Surg Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2026.111412_bib17","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1245\/s10434-022-11998-z","article-title":"Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases","volume":"29","author":"Chia","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111412_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/cancers12010116","article-title":"Long term survival after cytoreductive surgery combined with perioperative chemotherapy in gastric cancer patients with peritoneal metastasis","volume":"12","author":"Yonemura","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejso.2026.111412_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-60967-x","article-title":"Exosomal miR-493 suppresses MAD2L1 and induces chemoresistance to intraperitoneal paclitaxel therapy in gastric cancer patients with peritoneal metastasis","volume":"14","author":"Makinoya","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejso.2026.111412_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13063-022-06143-w","article-title":"SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation","volume":"23","author":"Bin","year":"2022","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.ejso.2026.111412_bib21","first-page":"211","article-title":"Efficacy of conversion surgery after neoadjuvant intraperitoneal-systemic chemotherapy in treating peritoneal metastasis of gastric cancer","volume":"26","author":"Li","year":"2021","journal-title":"J BUON"},{"issue":"19","key":"10.1016\/j.ejso.2026.111412_bib22","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2026.111412_bib23","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/fon-2021-1414","article-title":"A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis","volume":"18","author":"Lu","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejso.2026.111412_bib24","unstructured":"Yan C, Yang Z, Shi Z, Lu S, Shi M, Nie M, Chen J, Wu D, Mou Y, Xu Y, Wang Y. Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: results from the multicenter, randomized, phase 3 DRAGON-01 trial."},{"issue":"23","key":"10.1016\/j.ejso.2026.111412_bib25","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.3390\/jcm10235666","article-title":"Intraperitoneal chemotherapy as adjuvant or perioperative chemotherapy for patients with type 4 scirrhous gastric cancer: PHOENIX-GC2 trial","volume":"10","author":"Ishigami","year":"2021","journal-title":"J Clin Med"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:17:51Z","timestamp":1776154671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0748798326000314"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111412","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Normothermic catheter-based intraperitoneal chemotherapy: Systematic review using the IDEAL framework","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111412"}}